Financial Data and Key Metrics Changes - The company reported third quarter revenue of $189 million, a year-over-year increase of 22%, with 18% organic growth excluding acquisitions and currency impacts [18][19] - Adjusted gross profit was $101 million, up 28% year-over-year, with an adjusted gross margin of 53.3%, reflecting a 260 basis point increase year-over-year [20][21] - Adjusted net income was $26 million, a $2 million year-over-year increase, with adjusted fully diluted earnings per share of $0.46 compared to $0.43 in the same period of 2024 [23][24] Business Line Data and Key Metrics Changes - Process Analytics led growth with over 50% growth, including more than 30% growth at CTECH, while Filtration grew over 20% [6][15] - Consumable demand remained robust with greater than 20% growth, and Capital Equipment also saw over 20% growth [7][15] - Chromatography revenue grew mid-teens, driven by large column demand from key CDMO and pharma accounts globally [14] Market Data and Key Metrics Changes - Biopharma revenues grew over 20% year-over-year, with emerging biotech revenue at the highest level in nearly three years [9][10] - Asia Pacific saw approximately 50% growth, while the Americas grew 20% and EMEA was up low double digits [9][20] - China revenue returned to growth in Q3, although orders were slightly down, with expectations for recovery in 2026 [20][35] Company Strategy and Development Direction - The company is focusing on digitization as a key pillar of its strategic plan, with ongoing investments in analytics and process control technologies [10][11] - A partnership with Novasign was announced to integrate digital twin capabilities, aiming to optimize process development and manufacturing [11] - The Strategic Account Strategy initiative has successfully engaged with 20 large pharma and CDMO accounts, leading to increased cross-selling opportunities [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the overall strength across franchises, customers, and geographies, with a commitment to sustainable future growth [16][17] - The company is raising the midpoint of its organic growth guidance for 2025, reflecting strong performance and market conditions [9][25] - There is a focus on balancing cost efficiency and margin expansion with necessary investments to support future growth [29] Other Important Information - The company ended the third quarter with a cash position of $749 million, up $40 million sequentially, driven by strong operating cash flow [24][29] - Adjusted effective tax rate is expected to be between 21% to 22% for the year, about 100 basis points lower than previous guidance [23][29] Q&A Session Summary Question: Can you talk about the cadence of order momentum across the quarter? - Orders grew more than 20% in Q3, marking the sixth consecutive quarter of order growth, with no significant changes in growth patterns throughout the quarter [32][33] Question: Can you reconcile the sales guidance increase versus narrowing EBIT margin? - Margin performance was favorable, with operating income up about 20%, but one-time operating expenses and FX pressure impacted overall margins [38][39] Question: What do you make of customer conversations regarding onshoring activity? - The company is seeing increased interest in large hardware investments and expects first orders related to onshoring projects to come in the second half of 2026 [46][48] Question: Why is the guidance implying lower growth in Q4 compared to historical averages? - The guidance reflects less seasonality and a tougher comp in Q4, with expectations of 8% to 13% organic growth [50][52] Question: How is the company thinking about the gene therapy modality overall for 2026? - The company anticipates a 200 basis point headwind from a specific gene therapy customer but remains optimistic about overall growth due to a diversified portfolio [56][58]

Financial Data and Key Metrics Changes - The company reported third quarter revenue of $189 million, a year-over-year increase of 22%, with 18% organic growth excluding acquisitions and currency impacts [21][22] - Adjusted gross profit was $101 million, up 28% year-over-year, with an adjusted gross margin of 53.3%, reflecting a 260 basis point increase year-over-year [22][23] - Adjusted net income was $26 million, a $2 million year-over-year increase, with adjusted fully diluted earnings per share for the third quarter at $0.46 compared to $0.43 in the same period of 2024 [25][26] Business Line Data and Key Metrics Changes - Process Analytics led growth with over 50%, including more than 30% growth at CTECH, while Filtration grew over 20% [7][18] - Consumable demand remained robust with greater than 20% growth, and Capital Equipment also had over 20% growth [8][21] - Chromatography revenue grew mid-teens, driven by large column demand from key CDMO and pharma accounts globally [17] Market Data and Key Metrics Changes - Biopharma revenues grew over 20% year-over-year, with emerging biotech revenue at the highest level in nearly three years [11][21] - Asia Pacific saw approximately 50% growth, while the Americas grew 20% and EMEA was up low double digits [11][22] - China revenue returned to growth in Q3, although orders were slightly down, with expectations for recovery in 2026 [22][39] Company Strategy and Development Direction - The company is focusing on digitization as a key pillar of its strategic plan, with ongoing investments in analytics and process control technologies [12][19] - A partnership with Novasign was announced to integrate digital twin capabilities, aiming to optimize process development and manufacturing [13] - The Strategic Account Strategy initiative has successfully engaged 20 large pharma and CDMO accounts, leading to increased cross-selling opportunities [14] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery of small biotech and the overall health of the ecosystem, with a focus on capitalizing on growth strategies [11][39] - The company is raising the midpoint of its organic growth guidance for 2025, reflecting strong performance across franchises and geographies [10][27] - Management remains committed to balancing cost efficiency and margin expansion while investing in future growth opportunities [30][31] Other Important Information - The company expects adjusted effective tax rate for the year to be between 21% to 22%, about 100 basis points lower than previous guidance [25][31] - Cash position at the end of Q3 was $749 million, up $40 million sequentially, driven by strong operating cash flow performance [26][31] Q&A Session Summary Question: Can you talk about the cadence of order momentum across the quarter? - Management noted that orders grew more than 20% for the second consecutive quarter, with strong growth across all franchises and no significant changes in order patterns throughout the quarter [35][37] Question: Can you reconcile the sales guidance increase versus narrowing EBIT margin? - Management highlighted that while they are pleased with margin performance, they are making strategic investments in infrastructure and operations to support future growth, which impacts margins [42][44] Question: What is the outlook for onshoring activity and larger scale projects? - Management indicated that they are well-positioned to participate in upcoming onshoring projects, with expectations for first orders to come in the second half of 2026 [46][48] Question: How do you evaluate the performance of mid-sized CDMOs? - Management acknowledged strong performance from large-scale CDMOs but did not specifically address mid-sized CDMOs, indicating that large-scale accounts were the primary drivers of growth [92] Question: What trends are being observed in the Asia Pacific region? - Management confirmed that Asia Pacific represents about 15% of sales, with plans for further investments and a new office opening in Singapore, indicating a commitment to growing in the region [65][66]